Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 2/20 | 0.47 |
| ▸ | ENPEP | Q07075 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | GMNN | O75496 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18568609 | 0.87 | — | — | |
| SCHEMBL13165864 | 0.84 | — | — | |
| SCHEMBL13448317 | 0.82 | — | — | |
| SCHEMBL14540451 | 0.77 | — | — | |
| SCHEMBL13302739 | 0.77 | — | — | |
| SCHEMBL24287227 | 0.77 | — | — | |
| SCHEMBL550594 | 0.72 | — | — | |
| SCHEMBL3863769 | 0.72 | — | — | |
| SCHEMBL550638 | 0.72 | — | — | |
| SCHEMBL13411819 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9770442-B2 | Self-assembling amphiphilic polymers as anti-cancer agents | ALLEXCEL INC. (US) | 2017-09-26 | — | — | US | disclosed |
| US-9770442-B2 | Self-assembling amphiphilic polymers as anti-cancer agents | ALLEXCEL INC. (US) | 2017-09-26 | — | — | US | disclosed |
| EP-2167103-B1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTICANCER AGENTS | ALLEXCEL INC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2120974-B1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS | ALLEXCEL INC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-1979407-B1 | SOLUBILIZATION AND TARGETED DELIVERY OF DRUGS WITH SELF-ASSEMBLING AMPHIPHILIC POLYMERS | ALLEXCEL INC (US) | 2014-08-06 | — | — | EP | disclosed |
| US-8173764-B2 | Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers | ALLEXCEL INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-8173764-B2 | Solubilization and targeted delivery of drugs with self-assembling amphiphilic polymers | ALLEXCEL INC. (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100260743-A1 | Solubilization and Targeted Delivery of Drugs With Self-Assembling Amphiphilic Polymers | ALLEXCEL, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100260743-A1 | Solubilization and Targeted Delivery of Drugs With Self-Assembling Amphiphilic Polymers | ALLEXCEL, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-20100239659-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS | ALLEXCEL., INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100239659-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS | ALLEXCEL., INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100008938-A1 | SELF ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS | ALLEXCEL, INC. | 2010-01-14 | — | — | US | disclosed |
| US-20100008938-A1 | SELF ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS | ALLEXCEL, INC. | 2010-01-14 | — | — | US | disclosed |
| WO-2007084126-A1 | SOLUBILIZATION AND TARGETED DELIVERY OF DRUGS WITH SELF-ASSEMBLING AMPHIPHILIC POLYMERS | ALLEXCEL, INC. (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100008938-A1 | SELF ASSEMBLING AMPHIPHILIC POLYMERS AS ANTIVIRAL AGENTS | PICALM, CLTA, HAVCR2 | ANPEP 390/4885ENPEP 791/4885CYP3A4 4133/4885 |
| US-20100239659-A1 | SELF-ASSEMBLING AMPHIPHILIC POLYMERS AS ANTI-CANCER AGENTS | CD44, EPCAM, EGFR | ANPEP 1428/4885ENPEP 1774/4885CYP3A4 4163/4885 |
| US-20100260743-A1 | Solubilization and Targeted Delivery of Drugs With Self-Assembling Amphiphilic Polymers | CD44, ABCG2, ABCC1 | ANPEP 1899/4885ENPEP 2043/4885CYP3A4 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.